Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2

Ophthalmology

Volumn 122, Issue 3, 2015, Pages 545-554

  Campochiaro, Peter A ^a   Sophie, Raafay ^a   Tolentino, Michael ^b   Miller, Daniel M ^c   Browning, David ^d   Boyer, David S ^e   Heier, Jeffrey S ^f   Gambino, Laura ^g   Withers, Barbara ^g   Brigell, Mitchell ^g   Peters, Kevin ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Center for Retina and Macular Disease   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d Charlotte Eye Ear Nose and Throat   (United States)

^e RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^f OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^g Aerpio Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKB 9778; ANGIOPOIETIN RECEPTOR; HEMOGLOBIN A1C; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; RANIBIZUMAB; UNCLASSIFIED DRUG; AKB-9778; ANILINE DERIVATIVE; ENZYME INHIBITOR; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; SULFONIC ACID DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CENTRAL SUBFIELD THICKNESS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DIZZINESS; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EYE DISEASE; EYE TRACKER; FAINTNESS; FEMALE; HEMATOMA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OCULAR HYPEREMIA; OPEN STUDY; OPHTHALMOLOGICAL EQUIPMENT; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PRESYNCOPE; PRIORITY JOURNAL; RISK ASSESSMENT; SOMNOLENCE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VERY ELDERLY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; MACULAR EDEMA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; BLOOD PRESSURE; DIABETIC RETINOPATHY; ENZYME INHIBITORS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS, SUBCUTANEOUS; MACULAR EDEMA; MALE; MIDDLE AGED; RECEPTOR, TIE-2; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; SULFONIC ACIDS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84924082631     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.09.023     Document Type: Conference Paper

References (36)

1. R. Klein, B.E. Klein, and S.E. Moss The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema Ophthalmology 91 1984 1464 1474
2. Q.D. Nguyen, S.M. Shah, and E. Van Anden Supplemental oxygen improves diabetic macular edema: a pilot study Invest Ophthalmol Vis Sci 45 2003 617 624
3. Q.D. Nguyen, S. Tatlipinar, and S.M. Shah Vascular endothelial growth factor is a critical stimulus for diabetic macular edema Am J Ophthalmol 142 2006 961 969
4. Diabetic Retinopathy Clinical Research Network, M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
5. Q.D. Nguyen, D.M. Brown, D.M. Marcus RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
6. D.V. Do, Q.D. Nguyen, D. Boyer DA VINCI Study Group One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
7. C. Suri, P.F. Jones, and S. Patan Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
8. G. Thurston, C. Suri, and K. Smith Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1 Science 286 1999 2511 2514
9. P.C. Maisonpierre, C. Suri, and P.F. Jones Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 1997 55 60
10. S.F. Hackett, H. Ozaki, and R.W. Strauss Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization J Cell Physiol 184 2000 275 284
11. J.I. Patel, P.G. Hykin, and Z.J. Gregor Angiopoietin concentrations in diabetic retinopathy Br J Ophthalmol 89 2005 480 483
12. S.F. Hackett, S.J. Wiegand, G. Yancopoulos, and P. Campochiaro Angiopoietin-2 plays an important role in retinal angiogenesis J Cell Physiol 192 2002 182 187
13. Y. Oshima, T. Deering, and S. Oshima Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor J Cell Physiol 199 2004 412 417
14. Y. Oshima, S. Oshima, and H. Nambu Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive FASEB J 19 2005 963 965
15. S. Rangasamy, R. Srinivasan, and J. Maestas A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy Invest Ophthalmol Vis Sci 52 2011 3784 3791
16. A.M. Joussen, V. Poulaki, and A. Tsujikawa Suppression of diabetic retinopathy with angiopoietin-1 Am J Pathol 160 2002 1683 1693
17. A. Das, W. Fanslow, and D. Cerretti Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization Lab Invest 83 2003 1637 1645
18. H. Nambu, R. Nambu, and Y. Oshima Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier Gene Ther 11 2004 865 873
19. H. Nambu, N. Umeda, and S. Kachi Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization J Cell Physiol 204 2005 227 235
20. O.K. Yacyshyn, P.F. Lai, and K. Forse Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells Angiogenesis 12 2009 25 33
21. M. Winderlich, L. Keller, and G. Cagna VE-PTP control blood vessel development by balancing Tie-2 activity J Cell Biol 185 2009 657 671
22. J. Shen, M. Frye, and B.L. Lee Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature J Clin Invest 124 2014 4564 4576
23. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
24. F. Forooghian, P.J. Kertes, and K.T. Eng Alterations in the intraocular cytokine milieu after intravitreal bevacizumab Invest Ophthalmol Vis Sci 51 2010 2388 2392
25. G. Thurston, J.S. Rudge, and E. Ioffe Angiopoietin-1 protects the adult vasculature against plasma leakage Nat Med 6 2000 460 463
26. L. Pizurki, Z. Zhou, and K. Glynos Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production Br J Pharmacol 139 2003 329 336
27. N.R. London, K.J. Whitehead, and D.Y. Li Endogenous endothelial cell signaling systems maintain vascular stability Angiogenesis 12 2009 149 158
28. J.S. Lee, S.H. Song, and J.M. Kim Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor Cardiovasc Res 78 2008 572 580
29. R.W. Schrier, R.O. Estacio, P.S. Mehler, and W.R. Hiatt Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 3 2007 428 438
30. D. Ly, A.Z. Fu, and C. Hebert Cost effectiveness analysis of a hypertensive management program in patients with type 2 diabetes J Clin Hypertens (Greenwich) 11 2009 116 124
31. M.A. Creager, T.F. Luscher, F. Cosentino, and J.A. Beckman Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part 1 Circulation 108 2003 1527 1532
32. T. Nakagawa, K. Tanabe, and B.P. Croker Endothelial dysfunction as a potential contributor in diabetic nephropathy Nat Rev Nephrol 7 2011 36 44
33. M.M. Hartge, T. Unger, and U. Kintscher The endothelium and vascular inflammation in diabetes Diabetes Vasc Dis Res 4 2007 84 88
34. K. Miki, A. Miki, and M. Matsuoka Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor Ophthalmology 116 2009 1748 1754
35. B. Bakbak, B.T. Ozturk, and S. Gonul Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye J Ocul Pharmacol Ther 29 2013 728 732
36. L. Xu, T. Lu, and L. Tuomi Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach Invest Ophthalmol Vis Sci 54 2013 1616 1624